Context

Allergical rhinoconjunctivitis (ARC) and asthma are among the most prevalent chronic disorders affecting the US population, and contribute significantly to morbidity, direct and indirect healthcare costs and quality-of-life issues. Specific immunotherapy remains as a mainstay of treatment for these diseases and has traditionally been administered subcutaneously over an extended treatment period to desensitise allergical patients and improve their symptoms. Over the last several years, European regulatory authorities have approved1 the use of sublingual immunotherapy to treat allergical diseases and nearly 45% of allergen-specific immunotherapy is currently administered via this route in those countries.2 The advantages of sublingual immunotherapy over subcutaneous immunotherapy include ease of administration, avoidance of injections and convenience of home administration. In the USA, there are currently no …